The findings of a new study posted to the bioRxiv* preprint server showed that the intranasal SpyCage vaccine platform can be protective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and may prove to be a versatile and adaptable modality for the formulation of intranasal vaccines that target respiratory pathogens. The SARS-CoV-2 outbreak, which transpired into the global coronavirus disease 2019 (COVID-19) pandemic, could be partly controlled by widespread vaccinations. COVID-19 vaccines prevent both disease and infection transmission. The last few years have seen an avalanche of rapid vaccine developments that have proven highly effective. Until now, most approved SARS-CoV-2 vaccines require intramuscular (IM) administration. IM vaccines induce high levels of circulating antibodies, memory B cells, and effector CD4+ and CD8+ T cells. However, evidence confirming the induction of mucosal immunity in the respiratory tract by these vaccines remains lacking. In...
Latest health updates | Diseases | Latest News | Healthy lifestyle |